Who are Double-Blind Adalimumab/Placebo + MTX's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Humira, Abrilada, daclizumab, infliximab, Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab, Adalimumab, etanercept, infliximab, etanercept or adalimumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/double-blind-adalimumab-placebo-mtx.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Double-Blind Adalimumab/Placebo + MTX — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Double-Blind Adalimumab/Placebo + MTX (Double-Blind Adalimumab/Placebo + MTX) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-alpha inhibitor (monoclonal antibody). Area: Immunology.

phase 3 TNF-alpha inhibitor (monoclonal antibody) TNF-alpha Immunology Biologic Live · refreshed every 30 min

Target snapshot

Double-Blind Adalimumab/Placebo + MTX (Double-Blind Adalimumab/Placebo + MTX) — Abbott. Adalimumab is a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha signaling to reduce inflammation, combined with methotrexate for enhanced immunosuppressive effect.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Double-Blind Adalimumab/Placebo + MTX TARGET	Double-Blind Adalimumab/Placebo + MTX	Abbott	phase 3	TNF-alpha inhibitor (monoclonal antibody)	TNF-alpha
Humira	ADALIMUMAB	AbbVie	marketed	TNF blocker	Tumor Necrosis Factor-alpha (TNF-alpha)	2002-01-01
Abrilada	Adalimumab-Afzb	AbbVie	marketed	TNF blocker	Tumor necrosis factor-alpha (TNF-alpha)	2002-01-01
daclizumab, infliximab	daclizumab, infliximab	University of Iowa	marketed	Monoclonal antibody combination	IL-2 receptor alpha (CD25) and TNF-alpha
Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab	Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab	University of Helsinki	marketed	Combination immunosuppressive and anti-TNF therapy	Multiple: dihydrofolate reductase (methotrexate), TNF-alpha (infliximab), glucocorticoid receptor (prednisolone)
Adalimumab, etanercept, infliximab	Adalimumab, etanercept, infliximab	University of Padova	marketed	TNF-alpha inhibitor	TNF-alpha (tumor necrosis factor-alpha)
etanercept or adalimumab	etanercept or adalimumab	University of Glasgow	marketed	TNF-alpha inhibitor	TNF-alpha (tumor necrosis factor-alpha)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-alpha inhibitor (monoclonal antibody) class)

Abbott · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Double-Blind Adalimumab/Placebo + MTX — Competitive Intelligence Brief. https://druglandscape.com/ci/double-blind-adalimumab-placebo-mtx. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab